key: cord-1025350-c7y87ywc
authors: Medetalibeyoglu, Alpay; Bahat, Gulistan; Senkal, Naci; Kose, Murat; Avcı, Kader; Sayın, Gozde Yesil; Isoglu-Alkac, Ummuhan; Tukek, Tufan; Pehlivan, Sacide
title: Mannose binding lectin gene 2 (rs1800450) missense variant may contribute to development and severity of COVID-19 infection
date: 2021-01-27
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2021.104717
sha: e682d30b39426faff8cee5ebeeeeca28d0b39b53
doc_id: 1025350
cord_uid: c7y87ywc

BACKGROUND/OBJECTIVES: COVID-19 followed a mortal course in some young patients without any underlying factors, however, it followed a very benign course in some very older individuals with multiple comorbidities. These observations question if some genetic factors may be related to the vulnerability and poor prognosis of the disease. In this study, we aimed to investigate whether MBL2 gene B variant at codon 54 (rs1800450) were related to the variabilities in clinical course of this infection. METHODS: 284 PCR-confirmed COVID-19 patients and 100 healthy controls were included in the study. COVID-19 patients were subdivided according to the clinical features and clinical characteristics were analyzed. DNAs of all patients and controls were examined for the codon 54 A/B (gly54asp: rs1800450) variation in exon 1 of the MBL2 gene. RESULTS: In univariate analysis, BB genotype of MBL2 gene was more common among COVID-19 cases compared with controls (10.9% vs 1.0%, respectively; OR = 12.1, 95%CI = 1.6–90.1, p = 0.001). Multivariate analyses, adjusted for age, sex and MBL genetic variants, revealed that when compared with the COVID-19 patients that had AA genotype (reference), the patients that had BB or AB genotypes suffered from a higher risk for severe disease (for BB genotype, odds ratio (OR) = 5.3, p < 0.001; for AB genotype, OR = 2.9, p = 0.001) and for ICU need (for BB genotype, OR = 19.6, p < 0.001; for AB genotype, OR = 6.9, p = 0.001). On the other hand, there was not any significant difference between the genotype variants in terms of mortality at 28 days or development of secondary bacterial infection. CONCLUSION: The B variants of MBL2 gene at codon 54, which were associated with lower MBL2 levels, were related to a higher risk for a more severe clinical course of COVID-19 infection in some respects. Our findings may have potential future implications, e.g. for use of MBL protein as potential therapeutics or prioritize the individuals with B variants during vaccination strategies.

oligomerization, and (4) a 188-amino acid C-terminal carbohydrate recognition domain [13] .

The homozygous mutation, i.e., BB, results in the overall absence of the MBL2 protein, whereas heterozygous mutation; i.e., AB, results in a 5 to 10-fold reduction in serum MBL2 protein level when compared to the wild type, i.e., AA. The deficiency of MBL2 gene has been reported as associated with susceptibility to infectious and autoimmune diseases [14] .

In this report, therefore, we aimed to investigate whether MBL2 gene variant (rs1800450) may be related to the variable clinical courses observed interestingly in COVID-19 with a case-control study protocol.

We performed laboratory confirmation (RT-PCR examination) of SARS-CoV-2 in certified laboratories where RT-PCR assays were carried out in accordance with the protocol defined by the WHO [15] . The patients were considered to have severe disease when any of the following clinical and laboratory parameters are met: a respiratory rate of ≥30/min, suffering from dyspnea, peripheral oxygen saturation of < 90%, getting more than 5 L/min nasal oxygen supply, PaO2/FiO2 of ≤300, lactate of >2 mmol/L, hypotension (systolic blood pressure 40 mmHg lower than the usual systolic blood pressure) pulse of >100 beats/min, renal, hepatic, hematological (thrombocytopenia) or cerebral (confusion) dysfunction findings, presence of sepsis or septic shock, skin findings of capillary return disorder such as cutis marmorata and coldness, moderate/severe pneumonia (bilateral infiltration and/or multiple mottling and groundglass opacity), need for anticytokine therapy and/or broadspectrum antibacterial therapy.

We analyzed rs1800450 (c.161G>A p.Gly54Asp) representing one of the well-studied single nucleotide polymorphisms in the MBL2 gene. The patients were included between April-J o u r n a l P r e -p r o o f June 2020 that admitted to the COVID-19 center of a single university hospital. We included 100 healthy volunteers to serve as the control group. The patients and control groups were matched in terms of age and ethnic background. The institutional clinical research ethics committee approved the protocol (21/05/2020-84539). We isolated DNA from the collected blood by using the Genemark isolation kit (Genemark, USA). All of the patients and controls were examined for the codon 54 A/B (gly54asp: rs rs1800450) variation in exon 1 of the MBL2 gene.

Polymerase chain reaction (PCR) was performed using forward [16] . We selected 10% of the sample randomly and controlled the method on this sample (Figure 2 ).

We used IBM SPSS version 21.0 (IBM Corp. released 2012; Armonk, NY, USA) for the statistical analyses. Descriptive statistics included mean, standard deviation, median, minimum, maximum for the continuous variables after assessing the normality, frequency, and percentage for the nominal variables. Pearson Chi-square test with Yates correction or Fisher's exact test were used for 2X2 contingency tables when appropriate for non-numerical data. We performed multivariate binary logistic regression analyses to find out the association J o u r n a l P r e -p r o o f between different genetic variants of the MBL2 gene with study parameters. The results were adjusted for age and sex. Consequently, we have given the odds ratio (OR) and 95% confidence interval (CI) for the association of MBL gene variants with the study parameters.

We used the Hosmer&Lemeshow goodness-of-fit statistic to assess model fit for all regression models. Hardy Weinberg Equilibrium (HWE) was calculated using the De-Finetti program (online HWE and Association Testing-Institut für Humangenetik, Munich, Germany). Statistical significance was accepted as p<0.05 for the results of all analyses.

A total of 284 cases and 100 controls were enrolled in the study. We outlined the clinical features and treatment regimens of COVID-19 patients in Table 1 . The most common comorbidities were hypertension (24.5%) and diabetes mellitus (12.7%). With the prespecified classification, the severe disease was observed in 33.1%. In the follow-up, at day 28, mortality had occurred in 9 patients (3.2%) , and 6.3% had needed intensive unit care. The prevalence of BB genotype was significantly more common in COVID- 19 Table 3) . On the other hand, there was not any significant difference between the genotype variants in terms of mortality at 28 days or development of secondary bacterial infection ( Table 4, Table 5 ).

The main findings of this case-control study were as follows: in univariate analysis, the MBL BB genotype was significantly more common among COVID-19 cases when compared with controls. Multivariate analyses revealed that when compared with the COVID-19 patients that had AA genotype, the patients that had BB or AB genotypes suffered from a higher risk for severe disease and for ICU need ( Table 2 and Table 3 ). On the other hand, there was not any significant difference between the genotype variants in terms of mortality at 28 days or development of secondary bacterial infection ( Table 4 and Table 5 

In summary, it is the first time that an association between an MBL polymorphism and increased susceptibility and a more severe course of SARS-CoV-2 infection has been shown by this study. Future studies are needed in different populations, preferably with a higher case number. Nevertheless, the information on genetic factors that contribute to the pathogenesis and severity of COVID-19 disease is currently been highly warranted. These insights have the potential to contribute to the control of the outgoing pandemic and improve treatment outcomes. 

Clinical features of patients infected with 2019 novel coronavirus in

SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat

Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

SARS-CoV-2 viral load predicts COVID-19 mortality

Obesity as a predictor for a poor prognosis of COVID-19: A systematic review

Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?

Human Genetic Determinants of Viral Diseases

Association between polymorphisms in mannose-binding lectin 2 gene with pulmonary tuberculosis susceptibility

Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation

World Health Organization. Laboratory testing for

The polymorphisms of the MBL2 and MIF genes associated with

Pediatric Cochlear Implant Patients

Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm

Human non-synonymous SNPs: server and survey

REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants

Predicting the functional impact of protein mutations: application to cancer genomics

Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information

ProTherm, version 4.0: thermodynamic database for proteins and mutants

An integrated map of genetic variation from 1,092 human genomes

Human lectins and their roles in viral infections

Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10

Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS

Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1

Human mannan-binding lectin inhibits the infection of influenza A virus without complement

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry

A single asparagine-linked glycosylation site of the severe acute coronavirus infection

Complement-mediated neutralization of dengue virus requires mannose-binding lectin

Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin

High-dose mannose-binding lectin therapy for Ebola virüs infection

Mannose-binding lectin gene polymorphism and its impact on human immunodeficiency virus 1 infection

Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population

Immunological analysis in paediatric HIV patients at different stages of the disease

Mannose-binding lectin gene polymorphisms are not associated with susceptibility to hepatitis C virus infection in the Brazilian Amazon region

Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: its relation to disease progression and response to treatment. Hepat Mon

No Association between Mannose-Binding Lectin Alleles and Susceptibility to Chronic Hepatitis B Virus Infection in German Patients

Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection

Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection

Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans

Data curation and formal analysis: Murat Kose, Naci Senkal Funding acquisition: Ummuhan Isoglu-Alkac Investigation: Sacide Pehlivan, Kader Avci

Authors would like to thank Merve Oren and Mustafa Pehlivan for their contribution to statistical analyses, and Akın Tekcan for his contribution to bioinformatics analysis.

The authors didn't receive any writing assistance.

Project (TSG-2020-36785).The study protocol was approved by the Istanbul University, Istanbul Medical School ethics committee (21/05/2020-84539) This study conducted according to the guidelines laid down in the Declaration of Helsinki.This manuscript, including related data and tables has not been previously published.

All authors have read and approved the version to be submitted. All authors had access to all the study data, take responsibility for the accuracy of the analysis, and had authority over manuscript preparation and the decision to submit the manuscript for publication.The authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.